






Who we are
ADMdx specializes in brain image analysis to enable diagnosis, prognosis, and drug effect detection for Alzheimer's disease and various other forms of dementia. We provide pharmaceutical companies with powerful information to improve clinical trial success. ADMdx provides image data analysis and full CNS imaging study services with structural MRI, amyloid PET, tau PET, FDG PET, ASL, fMRI BOLD, and DTI. We are developing diagnostic products to enable early, accurate disease detection supporting optimal patient care.
News & events
ADMdx publishes results of Alzheimer’s disease clinical trial of rasagiline with the Cleveland Clinic
February 15, 2021 – ADM Diagnostics (ADMdx) has published its findings from a study of the drug rasagiline in patients with Alzheimer’s disease. ADMdx performed the image analysis for this study, which was led by Dr. Jeffrey Cummings of the Lou Ruvo Center for Brain Health, Cleveland Clinic. ADMdx applied methods of measuring changes in […]
See full postADMdx receives patent for novel method to detect and correct for PET brain scan variability
November 3, 2020 – ADM Diagnostics has received a patent on a novel method to detect and adjust for variability in PET scans. PET scans of the brain can measure abnormal proteins such as amyloid or tau, and other characteristics. In developing treatments for disease, it is very important to be able to measure small […]
See full postADMdx awarded patent on determining information using the early timeframes of a PET scan
September 30, 2020 – ADM Diagnostics has received a patent on a method that obtains information from a brain scan that would typically take much longer to measure. The first few minutes of a positron emission tomography (PET) scan contain information regarding brain blood flow and function. Information regarding the amount of amyloid burden or […]
See full postADMdx to present at the Tau2020 Conference on February 12
ADMdx will present findings regarding the presence of tau, an abnormal protein, in Alzheimer’s patients, at the Tau2020 conference to be held in Washington DC on February 12. This work describes the diverse burden of tau in individuals with Alzheimer’s disease, and relationships to brain atrophy, glucose metabolism, age, gender, and clinical status.
See full postADMdx to present insights to relationships between tau, glucose metabolism, and atrophy using PET and MRI imaging
ADMdx will present findings regarding relationships between tau, glucose metabolism, brain atrophy, and patient characteristics at the ADPD conference in April 2020. These analyses used a unique data set acquired through the Phase II study of the drug rasagiline in Alzheimer’s disease patients in collaboration with Dr. Jeffrey Cummings of the Cleveland Clinic. The data […]
See full postADMdx presents results of a Phase II clinical trial of rasagiline in collaboration with the Cleveland Clinic
Dawn Matthews, CEO, presented results of ADMdx’s analysis of image data for a Phase II clinical trial of the drug rasagiline in Alzheimer’s disease patients at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego. The trial was led by Dr. Jeffrey Cummings of the Lou Ruvo Center for Brain Health at the […]
See full postDawn Matthews, CEO, speaks at the Alzheimer’s Drug Discovery Foundation Nov. 1 luncheon
Dawn Matthews, ADMdx CEO, was one of three speakers in an invited panel presentation at the Alzheimer’s Drug Discovery Foundation (ADDF) luncheon on November 1, 2019 in New York. The panelists described the results of their studies, each focused on repurposing currently approved medications for use in Alzheimer’s disease. Ms. Matthews related the successful outcome […]
See full postNew results from ADMdx’s image analyses in Down syndrome published
New results from ADMdx’s collaborative work on the Down syndrome Biomarker Initiative (DSBI) study led by Dr. Michael Rafii of the University of Southern California has been published. These results show the correlation between imaging biomarkers and increases in NeuroFilament Light (NF-L), a blood-based marker of neurodegeneration. The manuscript is published in the journal Alzheimer’s […]
See full postADMdx to present results of dementia differentiation using MRI, FDG, and early frame amyloid imaging at AAIC
ADMdx will present the results of machine learning classification of different Alzheimer’s disease variants and non Alzheimer’s dementias using three different modalities: structural MRI, glucose metabolism using FDG PET, and early timeframes of amyloid PET scans. This work was conducted in collaboration with researchers from the Memory and Aging Center of the University of California, […]
See full postOur machine learning analysis of Traumatic Brain Injury image data to be presented at AAIC
ADMdx will present the results of machine learning classification of brain images from impaired and unimpaired boxers, and their differentiation from Alzheimer’s disease images, at the Alzheimer’s Association International Conference on July 22, 2018. This work was conducted in collaboration with Dr. Charles Bernick and other researchers at the Cleveland Clinic, using structural MRI scans […]
See full post